VIATRIS INC. Deferred Income Tax Expense (Benefit)
VIATRIS INC. (VTRS) reported Deferred Income Tax Expense (Benefit) of -$194.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-06
- VIATRIS INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$124.50M.
- VIATRIS INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$69.70M.
- VIATRIS INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$248.20M.
- VIATRIS INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$137.20M.
- VIATRIS INC. deferred income tax expense (benefit) for fiscal 2025 was -$476.50M.
- VIATRIS INC. deferred income tax expense (benefit) for fiscal 2024 was -$767.60M.
- VIATRIS INC. deferred income tax expense (benefit) for fiscal 2023 was -$387.10M.
- VIATRIS INC. deferred income tax expense (benefit) for fiscal 2022 was -$25.90M, a 103.83% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 7 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$124.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$194.20M 10-Q · filed 2026-08-06 | -$442.40M derived: sum of 3 quarters · filed 2026-08-06 | -$579.60M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$69.70M 10-Q · filed 2026-05-07 | -$317.90M derived: sum of 2 quarters · filed 2026-05-07 | -$455.10M derived: sum of 3 quarters · filed 2026-05-07 | -$502.60M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$248.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$385.40M derived: sum of 2 quarters · filed 2026-02-26 | -$432.90M derived: sum of 3 quarters · filed 2026-08-06 | -$476.50M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$137.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$184.70M derived: sum of 2 quarters · filed 2026-08-06 | -$228.30M 10-Q · filed 2025-11-06 | -$477.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$47.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$91.10M 10-Q · filed 2026-08-06 | -$340.00M derived: sum of 3 quarters · filed 2026-08-06 | -$652.40M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$43.60M 10-Q · filed 2026-05-07 | -$292.50M derived: sum of 2 quarters · filed 2026-05-07 | -$604.90M derived: sum of 3 quarters · filed 2026-05-07 | -$759.30M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$248.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$561.30M derived: sum of 2 quarters · filed 2026-02-26 | -$715.70M derived: sum of 3 quarters · filed 2026-02-26 | -$767.60M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$312.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$466.80M derived: sum of 2 quarters · filed 2025-11-06 | -$518.70M 10-Q · filed 2025-11-06 | -$725.90M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$154.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$206.30M 10-Q · filed 2025-08-07 | -$413.50M derived: sum of 3 quarters · filed 2026-02-26 | -$498.50M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$51.90M 10-Q · filed 2025-05-08 | -$259.10M derived: sum of 2 quarters · filed 2026-02-26 | -$344.10M derived: sum of 3 quarters · filed 2026-02-26 | -$412.30M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$207.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$292.20M derived: sum of 2 quarters · filed 2026-02-26 | -$360.40M derived: sum of 3 quarters · filed 2026-02-26 | -$387.10M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$85.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$153.20M derived: sum of 2 quarters · filed 2024-11-07 | -$179.90M 10-Q · filed 2024-11-07 | -$26.30M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$68.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$94.90M 10-Q · filed 2024-08-08 | $58.70M derived: sum of 3 quarters · filed 2025-02-27 | $36.80M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$26.70M 10-Q · filed 2024-05-09 | $126.90M derived: sum of 2 quarters · filed 2025-02-27 | $105.00M derived: sum of 3 quarters · filed 2025-02-27 | $200.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $153.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $131.70M derived: sum of 2 quarters · filed 2025-02-27 | $26.90M derived: sum of 3 quarters · filed 2025-02-27 | -$25.90M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$21.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$126.70M derived: sum of 2 quarters · filed 2023-11-08 | -$179.50M 10-Q · filed 2023-11-08 | -$232.40M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | -$104.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$157.60M 10-Q · filed 2023-08-07 | -$210.50M derived: sum of 3 quarters · filed 2024-02-28 | -$63.50M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | -$52.80M 10-Q · filed 2023-05-08 | -$105.70M derived: sum of 2 quarters · filed 2024-02-28 | $41.30M derived: sum of 3 quarters · filed 2024-02-28 | $334.50M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$52.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $94.10M derived: sum of 2 quarters · filed 2024-02-28 | $387.30M derived: sum of 3 quarters · filed 2024-02-28 | $675.70M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $147.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $440.20M derived: sum of 2 quarters · filed 2022-11-07 | $728.60M 10-Q · filed 2022-11-07 | $725.80M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $293.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $581.60M 10-Q · filed 2022-08-08 | $578.80M derived: sum of 3 quarters · filed 2023-02-27 | $488.10M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $288.40M 10-Q · filed 2022-05-09 | $285.60M derived: sum of 2 quarters · filed 2023-02-27 | $194.90M derived: sum of 3 quarters · filed 2023-02-27 | ||
| 2020-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$93.50M derived: sum of 2 quarters · filed 2023-02-27 | -$213.20M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | -$90.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$210.40M 10-Q · filed 2021-11-08 | |||
| 2020-09-27 | $67.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$8.10M derived: sum of 2 quarters · filed 2021-08-09 | -$52.00M 10-Q · filed 2020-11-10 | ||
| 2020-06-30 | -$75.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$119.70M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$43.90M 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | -$192.60M 10-K · filed 2022-02-28 | ||||
| 2019-09-29 | $0.00 10-Q · filed 2020-11-10 | ||||
| 2018-12-31 | -$264.30M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |